Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 120, Issue 1, Pages 88-96
Publisher
Springer Nature
Online
2018-10-30
DOI
10.1038/s41416-018-0298-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment
- (2018) Herve Tiriac et al. GASTROINTESTINAL ENDOSCOPY
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
- (2018) Georgios Vlachogiannis et al. SCIENCE
- Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
- (2016) Mark J. Selby et al. PLoS One
- Immune checkpoint therapy for pancreatic cancer
- (2016) Henrik Johansson et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Prognostic value of PDL1 expression in pancreatic cancer
- (2016) David J. Birnbaum et al. Oncotarget
- Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis
- (2016) Madison Black et al. Oncotarget
- Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer
- (2016) Marcela D'Alincourt Salazar et al. OncoImmunology
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Organoid Models of Human and Mouse Ductal Pancreatic Cancer
- (2015) Sylvia F. Boj et al. CELL
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
- (2015) Jan Trøst Jørgensen EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
- (2015) Keith M. Kerr et al. Journal of Thoracic Oncology
- CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist
- (2015) Sangjun Lee et al. Molecular Oncology
- Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration
- (2015) Caroline A. Lindemans et al. NATURE
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
- (2015) Richard A Moffitt et al. NATURE GENETICS
- Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids
- (2015) Ling Huang et al. NATURE MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Phenotypic screening in cancer drug discovery — past, present and future
- (2014) John G. Moffat et al. NATURE REVIEWS DRUG DISCOVERY
- In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
- (2014) C. Wang et al. Cancer Immunology Research
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- Roles for KRAS in Pancreatic Tumor Development and Progression
- (2013) Marina Pasca di Magliano et al. GASTROENTEROLOGY
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
- (2013) Dung T. Le et al. JOURNAL OF IMMUNOTHERAPY
- Development and Histopathological Characterization of Tumorgraft Models of Pancreatic Ductal Adenocarcinoma
- (2013) Patrick L. Garcia et al. PLoS One
- Growing Self-Organizing Mini-Guts from a Single Intestinal Stem Cell: Mechanism and Applications
- (2013) T. Sato et al. SCIENCE
- Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells
- (2012) Eileen L Heinrich et al. Journal of Translational Medicine
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of Anti-Malarial Compounds as Novel Antagonists to Chemokine Receptor CXCR4 in Pancreatic Cancer Cells
- (2012) Joseph Kim et al. PLoS One
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- CC Chemokine Receptor 9 Enhances Proliferation in Pancreatic Intraepithelial Neoplasia and Pancreatic Cancer Cells
- (2009) Xiaoming Shen et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Chemokine Receptor CXCR4 Enhances Proliferation in Pancreatic Cancer Cells Through AKT and ERK Dependent Pathways
- (2009) Xiaoming Shen et al. PANCREAS
- The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia
- (2008) R M Thomas et al. GUT
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More